Outlook Therapeutics
OTLK----
Outlook Therapeutics (OTLK)
Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for ophthalm...
- Open
- --
- High
- --
- Low
- --
- Prev. Close
- --
- Volume
- --
- Turnover
- --
- Avg Price
- --
- Bid/Ask Ratio
- --
- Amplitude
- --
- 52wk High
- --
- Volume Ratio
- --
- Turnover Ratio
- --
Outlook Therapeutics Analyst Rating
View MoreForecast & Rating
Jul 24, 2026Price forecast
$5.50291.46%
Forecast & RatingBuy
4analysts
- Strong buy50.00%
- Buy0.00%
- Hold50.00%
- Sell0.00%
- Strong sell0.00%
News
- Global Report · 19 hours ago
FDA Approvals and Earnings Beats Propel Specialized US-Listed Firms
- Global Report · 1 day ago, 04:18 AM
Niche U.S. Equities Face Commercial and Regulatory Tests in Mid-2026
- Global Report · 1 day ago, 04:13 AM
From Web3 Pivots to AI Robotics Deals: Tracking Capital Shakeups Across U.S. Equities
- StockTitan · 2 days ago, 05:40 AM
Outlook Therapeutics Announces LYTENAVA™ FDA Approval as the First and Only FDA-Approved Ophthalmic Bevacizumab for the Treatment of Wet AMD | OTLK Stock News
- TradingView · 2 days ago, 05:03 AM
Outlook Therapeutics grants options to CEO Robert C. Jahr and CFO Lawrence A. Kenyon
- Global Report · 2 days ago, 04:13 AM
Beyond the Mega-Caps: AI Patent Wars, Housing Slowdowns, and the Market's Messy Middle
